Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 12/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26599121 | 0.80 | GSK3B (0.39) | GPR35GSK3BPOLB | |
| SCHEMBL18701663 | 0.79 | POLB (0.37) | GPR35TSHRPOLBTDP1L3MBTL1 | |
| SCHEMBL18701639 | 0.77 | TSHR (0.43) | GPR35GSK3BTSHRPOLBTDP1 | |
| SCHEMBL4584130 | 0.76 | GSK3B (0.59) | GPR35GSK3BTSHRPOLBTDP1 | |
| SCHEMBL28290159 | 0.76 | L3MBTL1 (0.56) | GPR35POLBTDP1L3MBTL1DAO | |
| SCHEMBL18701734 | 0.76 | DAO (0.42) | GPR35TSHRPOLBTDP1L3MBTL1 | |
| SCHEMBL15057811 | 0.75 | MAPT (0.42) | TSHRPOLBKDM4EPKM | |
| SCHEMBL1973884 | 0.74 | GPR35 (0.47) | GPR35GSK3BTSHRPOLBTDP1 | |
| SCHEMBL3281960 | 0.74 | GPR35 (0.47) | GPR35GSK3BTSHRPOLBTDP1 | |
| SCHEMBL8135224 | 0.73 | ALDH1A1 (0.47) | GPR35GSK3BTSHRPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4511355-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FundaMental Pharma GmbH (DE) | 2025-02-26 | — | — | EP | disclosed |
| CN-119522208-A | Effective methods for modulating NMDA receptor-mediated toxicity | 智基药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024223617-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| EP-3994130-B1 | SUBSTITUTED THIOPHENE CARBOXAMIDES AND DERIVATIVES THEREOF AS MICROBICIDES | BAYER AG (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-114364663-B | Substituted thiophenecarboxamides and derivatives thereof as microbiocides | 拜耳公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| CN-112724127-B | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
| CN-112724127-A | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2021-04-30 | — | — | CN | disclosed |
| WO-2021001331-A1 | SUBSTITUTED THIOPHENE CARBOXAMIDES AND DERIVATIVES THEREOF AS MICROBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020228817-A1 | ERK INHIBITOR AND USE THEREOF | 南京明德新药研发有限公司 | 2020-11-19 | — | — | WO | disclosed |
| CN-108203433-B | ROCK inhibitor and application thereof | 成都先导药物开发股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10081617-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3283464-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | TRPM4, GRM4, GRIN1 | GPR35 454/4885GSK3B 4226/4885TSHR 1639/4885 |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | GPR35 4080/4885GSK3B 366/4885TSHR 3525/4885 |
| US-10081617-B2 | Factor XIa inhibitors | F11, F2, TFPI | GPR35 4080/4885GSK3B 366/4885TSHR 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.